Join

Compare · AZN vs GRVI

AZN vs GRVI

Side-by-side comparison of AstraZeneca PLC (AZN) and Grove Inc. (GRVI): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both AZN and GRVI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • AZN is the larger of the two at $563.07B, about 8324.3x GRVI ($67.6M).
  • AZN has hit the wire 21 times in the past 4 weeks while GRVI has been quiet.
  • AZN has more recent analyst coverage (25 ratings vs 0 for GRVI).
MetricAZNGRVI
Company
AstraZeneca PLC
Grove Inc.
Price
$181.67-2.33%
$4.63+0.87%
Market cap
$563.07B
$67.6M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NYSE
NASDAQ
IPO
2026
2021
News (4w)
21
0
Recent ratings
25
0
AZN

AstraZeneca PLC

AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

GRVI

Grove Inc.

Grove, Inc., through its subsidiaries, engages in developing, producing, marketing, and selling raw materials, white label products, and end consumer products containing the industrial hemp plant extract, cannabidiol. The company serves consumer markets, including the botanical, beauty care, pet care, and functional food sectors. It also operates annual tradeshow related to the CBD industry in the United States. Grove, Inc. was incorporated in 2018 and is headquartered in Henderson, Nevada.

Latest AZN

Latest GRVI